About us

HAEMATO — Well Established

HAEMATO and all its employees are primarily oriented towards the needs of patients and customers in their daily work. Service, quality and reliability are essential elements of our customer orientation and at the same time drivers of further growth.

We will be happy to answer any questions or specific concerns you may have.

Ordering Service Germany

Phone 030 / 677 9867 – 600
Fax 030 / 677 9867 – 707

Ordering Service Austria

Phone 0800 / 293 527
Fax 0800 / 296 426

4,200 m² total area at the Site in Schönefeld

More than 7,000 customers

152 employees

28 apprentices since foundation

67 % female employees

For more than15 years, HAEMATO has been committed to actively help reduce costs in the healthcare system so that every patient can benefit from the latest therapies and treatment options, even if these are often very expensive.

With our product portfolio of off-patent and patent-protected pharmaceuticals, we contribute to an efficient supply of medicines, reducing costs for health insurance companies and thus for patients.

In the area of our own brands, the focus is on development, acquisition, licensing and distribution of prescription drugs and OTC products, special cosmetics as well as dietary supplements in the lifestyle and aesthetics sector.

Products and services of the medical-aesthetic market are increasingly in demand. Society, which is getting older and staying fit longer, wants to look their perceived age. Also due to the increased social acceptance of beauty medicine, the beauty market is a growing branch within the health market.

News

Find out about the current business development of HAEMATO AG as well as about our investor relations activities.

To the news archive

interim report

Ad-Hoc Mitteilung

HAEMATO continues to grow strongly: in the second quarter of 2021, preliminary consolidated revenue increased by around 41% to 77.6 million euros - after already growing by 22% in the first quarter of 2021. Preliminary half-year revenue for 2021 rose to 151.5 million euros, representing year-on-year growth of 31%. Preliminary EBIT rose to 4.8 …

interim report

Investor News

HAEMATO AG (ISIN: DE000289VV1), has continued its growth course in the first months of 2021. Due to a strong core business, consolidated sales (IFRS) increased by 22% to EUR 73.9 million in the first quarter of 2021. The specialist in drugs for the treatment of chronic diseases and for individual therapies increased earnings disproportionately at …

Ad hoc of HAEMATO AG pursuant to Art. 17 MAR: The Supervisory Board of HAEMATO AG approved the Executive Board’s proposal for the appropriation of profits at today’s balance sheet meeting. The Executive Board and Supervisory Board will therefore propose a dividend of EUR 1.00 per dividend-bearing share at the Annual General Meeting to be […]

Always there for you

Ordering Service Germany

Phone 030 / 677 9867 – 600
Fax 030 / 677 9867 – 707

Ordering Service Austria

Phone 0800 / 293 527
Fax 0800 / 296 426